Company intelligence / Profile preview

TDVax

Boston, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

TDVax is a pharmaceutical product and brand associated with the production of a combined Tetanus and Diphtheria Toxoids Adsorbed vaccine. It is primarily indicated for active immunization against tetanus and diphtheria in persons 7 years of age and older. The vaccine is manufactured by MassBiologics, the only non-profit FDA-licensed manufacturer of vaccines and biologics in the United States, which is part of the University of Massachusetts Medical School. TDVax is widely used for booster doses and in wound management to prevent tetanus infection while maintaining immunity against diphtheria.

Therapeutic areas: Infectious Diseases
Modalities: VaccineRecombinant protein
Industry: Academic Hospital/University/Research

Partnerships

University of Massachusetts Medical School

Beyond the preview

Go deeper on TDVax.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TDVax.

Explore the full profile